ZW-251
ZW-251 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) with topoisomerase-I inhibitory activity. ZW-251 induces cytotoxicity, penetrates tumor spheroids, exerts bystander cytotoxicity, and inhibits tumor growth in hepatocellular carcinoma models. ZW-251 can be used for the research of hepatocellular carcinoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Topoisomerase I |
In Vitro
ZW-251 (0.001-100 nM; 4 days) exhibits cell cytotoxicity to HepG2 spheroid liver cancer cell line[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys
[2] -
Dosage:20 mg/kg; 60 mg/kg; 120 mg/kg
-
Administration:i.v.; 3 doses at day 1, 22 and 43
-
Result:Was well tolerated in cynomolgus monkeys.
Exhibited dose-proportional PK.
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Patient-Derived Xenograft (PDX)
- Patient-Derived Orthotopic Xenograft (PDOX)
- Liver Cancer Modeling
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
SMILES
[ZW-251]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)